Content: cookies-message

We use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits. If you continue browsing the website, you accept its installation and use as aforementioned. You may modify the settings and obtain more information here

Close
Grifols
Search
 
Search
en 
  • es
Company Commitment Innovation Team Products and services Investors Careers Media Contact
Close
Content: intro-company

Company

Since 1909, Grifols has worked to improve the health and well-being of people around the world.

Our business is organized into four divisions: Bioscience, Diagnostic, Hospital and Bio Supplies.

Read more
  • Mission
  • Our values
  • Divisions
    • Bioscience
      • From donors to patients
      • Plasma journey
    • Diagnostic
    • Hospital
    • Bio Supplies
  • History
  • Grifols museum
    • La Casa: where it all began
    • The Plant: people helping people
    • The World: From family business to global company
  • Grifology
    • The Cabinet
Content: covid-19-destacado-1

Latest updates on COVID-19 

Read more
Content: company-destacado-1

We improve the health and well-being of patients around the world.

Read more
Content: company-destacado-2

Four business divisions united by a shared commitment to quality, safety and on-going innovation.

Read more
Close
Content: intro-commitment

Commitment

We are committed to a long-term vision that creates a sustainable, positive impact on the communities in which we operate.

Read more
  • Commitment to patients
    • Grifols Hemophilia Awareness
      Global Awards
      • Eligibility Criteria
      • How to apply
      • Award Recipients
      • Inquiries on the GHAGA
  • Commitment to science
  • The environment
  • Ethics and compliance
  • Foundations
Content: covid-19-destacado-1

Latest updates on COVID-19 

Read more
Content: commitment-destacado-1

Patients inspire the work we do every day.

Read more
Content: commitment-destacado-2

We support the development of the scientific community and its research efforts.

Read more
Close
Content: intro-innovation

Innovation

Since the founding of Grifols, our on-going innovation has helped shape industry standards in the plasma medicines sector.

Read more
  • Research areas
  • COVID-19
    • COVID-19 Plasma Therapies in Clinical Trials
    • COVID-19 Screening test
    • COVID-19 in the Media
  • AMBAR
    • Alzheimer's disease
    • The AMBAR hypothesis
    • The AMBAR study
    • The AMBAR results
    • AMBAR in the Media
Content: covid-19-destacado-1

Latest updates on COVID-19 

Read more
Content: innovation-destacado-2

AMBAR, check latest results on Grifols' lead project on Alzheimer's. 

Read more
Close
Content: intro-team

Team

The efforts of every member of the Grifols team enable us to achieve our mission of improving people's health and well-being.

Read more
  • Grifols culture
  • Global footprint
  • Training and development
Content: covid-19-destacado-1

Latest updates on COVID-19 

Read more
Content: team-destacado-1

We strive to cultivate a friendly, diverse and inclusive work environment.

Read more
Content: team-destacado-2

Grifols is becoming increasingly global. A diverse team will remain a key component to our future success.

Read more
Close
Content: intro-investors

Investors

Read more
  • Financials
    • Quarterly reports
    • Annual accounts
    • CNMV communications
    • SEC communications
    • Fixed income and credit ratings
    • Average period of payment to suppliers
  • Inside Information
  • Other Relevant Information
  • Relevant events
    up to December 31st, 2019
  • Agenda
  • Press releases
  • Corporate governance
    • Board of Directors
      • Committees
      • Regulations
    • General Shareholders’ Meeting
    • Annual corporate governance report
    • Directors' remuneration report
    • Articles of association
    • Corporate policies
  • Corporate Stewardship
  • Presentations
  • Stock information
    • Stock and share capital
      • Class A shares
      • Class B shares
      • ADR program
        • · ADR Level I
        • · ADR Level III
    • Dividends
    • Agreements between shareholders
    • Major holders and treasury stock
Close
Content: intro-careers

Careers

People are at the heart of our business. We are committed to continued investment in training and development.

Read more
Close
Content: intro-media

Media

Latest news about the company and contact information for journalists and communication professionals.

Read more
  • Media contacts
  • Newsroom
  • Company Statements
Close
Content: intro-contact

Contact

Headquartered in Barcelona, Spain, Grifols has more than 24,000 employees in 30 countries and regions. Contact us around the world.

Read more
  • International Headquarters
  • Adverse reactions – Pharmacovigilance
Grifols
Search
Show menu
   
Grifols
Search
Close
Company   Commitment   Innovation   Team   Products and services Investors   Careers   Media   Contact  
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Company Mission Our values Divisions   History Grifols museum   Grifology  
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Divisions Bioscience Diagnostic Hospital Bio Supplies
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Grifols museum La Casa: where it all began The Plant: people helping people The World: From family business to global company
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Grifology The Cabinet
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Commitment Commitment to patients   Commitment to science The environment Ethics and compliance Foundations
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Commitment to patients Grifols Hemophilia Awareness Global Awards
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Innovation Research areas COVID-19   AMBAR  
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
COVID-19 COVID-19 Plasma Therapies in Clinical Trials COVID-19 Screening test COVID-19 in the Media
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
AMBAR Alzheimer's disease The AMBAR hypothesis The AMBAR study The AMBAR results AMBAR in the Media
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Team Grifols culture Global footprint Training and development
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Products and services
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Investors Financials   Inside Information Other Relevant Information Relevant events up to December 31 st , 2019 Agenda Press releases Corporate governance   Corporate Stewardship Presentations Stock information  
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Financials Quarterly reports Annual accounts CNMV communications SEC communications Fixed income and credit ratings Average period of payment to suppliers
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Corporate governance Board of Directors General Shareholders’ Meeting Annual corporate governance report Directors' remuneration report Articles of association Corporate policies
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Stock information Stock and share capital Dividends Agreements between shareholders Major holders and treasury stock
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Careers
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Media Media contacts Newsroom Company Statements
English
  • Spanish
Content: footer-content-logos

Follow

Grifols
Search
BACK
Contact International Headquarters Adverse reactions – Pharmacovigilance
English
  • Spanish
Content: footer-content-logos

Follow

DIRECTORS' REMUNERATION REPORT

Directors' remuneration report

Directors' Remuneration Policy

The Directors' Remuneration Report was approved by the Ordinary General Shareholders Meeting held 26 May 2017 and will be valid for the next three years, unless amended by the Grifols General Shareholders Meeting.

Directors' Remuneration Policy

Previous
2019 2018 2017 2016 2015 Previous
Next

2019

Annual report 2019

2019 Annual report on Directors' remuneration (translation from the original in Spanish)

2018

Annual report 2018

2018 annual report on Directors' remuneration (translation from the original in Spanish)

2017

Annual report 2017

2017 annual report on Directors' remmuneration (translation from the original in Spanish)

2016

Annual report 2016

2016 annual report on Directors' remuneration (translation from the original in Spanish)

2015

Annual report 2015

2015 annual report on Directors' remuneration (translation from the original in Spanish)

2014

Annual report 2014

2014 annual report on Directors' remuneration (translation from the original in Spanish)

2013

Annual report 2013

2013 annual report on Directors' remuneration (spanish version)

Previous

2012

2012 annual report on Directors' remuneration

2011

2011 annual report on Directors' remuneration

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

Content: footer-content-logos

Follow

Content: copyright

© 2020 Grifols, S.A. All rights reserved worldwide.
Content: footer-content-links-1

ABOUT US

Company

Commitment

Innovation

Team

Products & services

Investors

Careers

Media

Content: footer-content-links-2

TOP WEBSITES

Grifols Plasma

Grifols Academy

Grifols Scientific Awards

Grifols Engineering

Fundación Grifols

Fundación Probitas

Content: footer-content-links-3-sense-site-map

HELP

Privacy notices

Cookies policy

Terms of use

Contact

Content: copyright

© 2020 Grifols, S.A. All rights reserved worldwide.
Content: grifols-welcome-popup
Discover our new corporate site

Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.

Enter
Content: hcp-products-popup

This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.

Are you a healthcare professional?

Yes
No